Idelalisib

Idelalisib (Zydelig) is a prescription medication used to treat certain types of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is a type of chemotherapy drug, known as a kinase inhibitor. Idelalisib works by blocking certain proteins which help cancer cells grow and divide. It is usually used in combination with another chemotherapy drug, rituximab.

Idelalisib is a prescription medication used to treat certain types of blood cancers, particularly those affecting B-cells, a type of white blood cell. Here's a breakdown of its key features:

Conditions Treated:

• Chronic Lymphocytic Leukemia (CLL): Idelalisib is primarily used in combination with other chemotherapy drugs to treat adults with CLL, a cancer of mature lymphocytes (B-cells) in the blood and bone marrow.
• Follicular Lymphoma (FL): In some cases, it may also be used for FL, another cancer that originates from B-cells. FL typically affects the lymph nodes.

How it Works:

• PI3K Inhibitor: Idelalisib belongs to a class of drugs called phosphatidylinositol-3-kinase (PI3K) inhibitors. The PI3K pathway is a signaling cascade involved in cell growth, proliferation, and survival. In some cancers, including CLL and FL, this pathway is abnormally activated, promoting uncontrolled growth of B-cells. Idelalisib works by blocking a specific enzyme (PI3K) within this pathway, thereby inhibiting the signals that drive cancer cell growth and survival.

Administration:

• Oral Tablets: Idelalisib comes as tablets taken orally, typically once or twice daily with food.

Important Considerations:

• Combination Therapy: Idelalisib is rarely used alone and is typically combined with other chemotherapy drugs to achieve a more effective treatment approach for CLL and FL.
• Side Effects: Idelalisib can cause side effects, including diarrhea, nausea, cough, rash, and increased risk of infection. Regular monitoring by a doctor is essential during treatment.
• Not for Everyone: Idelalisib is not suitable for everyone and has specific restrictions based on medical history and other factors. Consulting a doctor is crucial to determine if it's the right treatment option.
• Close Monitoring: Due to potential side effects, particularly pneumonitis (inflammation of the lungs), close monitoring by a doctor experienced in treating CLL and FL is essential

Additional Notes:

• Idelalisib offers a targeted treatment approach for CLL and FL by interrupting a specific pathway involved in cancer cell growth.
• If you have CLL or FL and are considering Idelalisib, talking to your doctor is essential. They can provide more specific information about its benefits and risks based on your individual situation and medical history.
• Clinical trials are ongoing to explore the use of Idelalisib in combination with other therapies or for other types of blood cancers.